Resveratrol Inhibits Cardiac Hypertrophy via AMP-activated Protein Kinase and Akt
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Whereas studies involving animal models of cardiovascular disease demonstrated that resveratrol is able to inhibit hypertrophic growth, the mechanisms involved have not been elucidated. Because studies in cells other than cardiomyocytes revealed that AMP-activated protein kinase (AMPK) and Akt are affected by resveratrol, we hypothesized that resveratrol prevents cardiac myocyte hypertrophy via these two kinase systems. Herein, we demonstrate that resveratrol reduces phenylephrine-induced protein synthesis and cell growth in rat cardiac myocytes via alterations of intracellular pathways involved in controlling protein synthesis (p70S6 kinase and eukaryotic elongation factor-2). Additionally, we demonstrate that resveratrol negatively regulates the calcineurin-nuclear factor of activated T cells pathway thus modifying a critical component of the transcriptional mechanism involved in pathological cardiac hypertrophy. Our data also indicate that these effects of resveratrol are mediated via AMPK activation and Akt inhibition, and in the case of AMPK, is dependent on the presence of the AMPK kinase, LKB1. Taken together, our data suggest that resveratrol exerts anti-hypertrophic effects by activating AMPK via LKB1 and inhibiting Akt, thus suppressing protein synthesis and gene transcription.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Resveratrol treatment activates SIRT1, PGC-1α and AMPK [29, 145-148] and inhibits AKT [149] (Figure 4).”
From PGC-1α in aging and anti-aging interventions (2009) · cites this paper as [149]
In the citing paper
“The loss of AMPK activity is believed to be pro-hypertrophic because lines of molecular signaling pathways that control cell growth are attenuated by AMPK activation [197,198,199].”
From AMPK, Mitochondrial Function, and Cardiovascular Disease (2020) · cites this paper as [197]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Activation of the AMP-activated Protein Kinase by the Anti-diabetic Drug Metformin in Vivo
Zou, M.-H., Kirkpatrick, S. S., Davis, B. J., Nelson, J. S., Wiles, W. G., Schlattner, U., Neumann, D., Brownlee, M., Freeman, M. B., & Goldman, M. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404421200 · Cited by 478
RetractedInhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
Shiojima, I. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24682 · Cited by 939
SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase
Hou, X., Xu, S., Maitland-Toolan, K. A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T. J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802187200 · Cited by 778
Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy
Wilkins, B. J., Dai, Y.-S., Bueno, O. F., Parsons, S. A., Xu, J., Plank, D. M., Jones, F., Kimball, T. R., & Molkentin, J. D. (2004) · Circulation Research · doi:10.1161/01.res.0000109415.17511.18 · Cited by 761
Ouchi, N., Kobayashi, H., Kihara, S., Kumada, M., Sato, K., Inoue, T., Funahashi, T., & Walsh, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310389200 · Cited by 759
Resveratrol stimulates AMP kinase activity in neurons
Dasgupta, B., & Milbrandt, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610068104 · Cited by 723
Adiponectin-mediated modulation of hypertrophic signals in the heart
Shibata, R., Ouchi, N., Ito, M., Kihara, S., Shiojima, I., Pimentel, D. R., Kumada, M., Sato, K., Schiekofer, S., Ohashi, K., et al. (2004) · Nature Medicine · doi:10.1038/nm1137 · Cited by 671
Research works printed but not linked: 2
- Liu, Z., Song, Y., Zhang, X., Liu, Z., Zhang, W., Mao, W., Wang, W., Cui, W., Zhang, X., Jia, X., Li, N., Han, C., and Liu, C. (2005) Clin. Exp. Phar- macol. Physiol. 32, 1049 -1054
- Hou, X., Xu, S., Maitland-Toolan, K. A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T. J., Cohen, R. A., and Zang, M. (2008) J. Biol. Chem.
Cited by
Items 101–200 of 244
Resveratrol inhibits right ventricular hypertrophy induced by monocrotaline in rats
Yang, D., Zhang, H., Xu, Y., Gao, Y., Yang, X., Hao, X., & Li, X. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05231.x · Cited by 60
Translating cell survival and cell longevity into treatment strategies with SIRT1.
Maiese, K., Chong, Z. Z., Shang, Y., & Wang, S. (2011) · PubMed · Cited by 67
SIRT1: Role in cardiovascular biology
Ma, L., & Li, Y. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.036 · Cited by 64
“Resveratrol action on AMPK is SIRT1 dependent [100,101], others suggest that SIRT1 is dispensable for resveratrol-induced AMPK-activation [99,102].”
BackgroundHedayati, N., Yaghoobi, A., Salami, M., Gholinezhad, Y., Aghadavood, F., Eshraghi, R., Aarabi, M. H., Homayoonfal, M., Asemi, Z., Mirzaei, H., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1174816 · Cited by 62
“p70S6K, eEF2, and NFAT signaling pathways (105).”
Kandadi, M. R., Panzhinskiy, E., Roe, N. D., Nair, S., Hu, D., & Sun, A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.07.004 · Cited by 58
Manda, G., Checheriţă, I. A., Comanescu, M. V., & Hinescu, M. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/604208 · Cited by 62
“Decreased expression and activity of the deacetylase SIRT1 favor high glucose-induced mesangial hypertrophy through downregulation of theAMPK signaling pathway and subsequent activation of mTOR [93, 94].”
BackgroundChen, B., Ma, Y., Meng, R., Xiong, Z., Wang, H., Zeng, J., Liu, C., & Dong, Y. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.73 · Cited by 56
Meng, R., Pei, Z., Yin, R., Zhang, C., Chen, B., Zhang, Y., Liu, D., Xu, A., & Dong, Y. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.024 · Cited by 55
“Previous studies by others suggested that the AMPK plays a role in the development of cardiac hypertrophy (Chan et al., 2008, 2004).”
BackgroundResultA Computational Method for Unveiling the Target Promiscuity of Pharmacologically Active Compounds
Schneider, P., & Schneider, G. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201706376 · Cited by 52
mTOR: more targets of resveratrol?
Widlund, A. L., Baur, J. A., & Vang, O. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.11 · Cited by 52
Lacerda, D. D. S., Türck, P., Seolin, B. G. D. L., Colombo, R., Ortiz, V. D., Bonetto, J. H. P., Carraro, C. C., Bianchi, S. E., Belló‐Klein, A., Bassani, V. L., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13948 · Cited by 57
“Similarly, resveratrol produces anti-hypertrophic effects in rat cardiomyocytes, both in vitro and in vivo, by activating AMP-activated protein kinase and inhibiting PKB (Akt), reducing the content and rate of protein synthesis (Chan et al., 2008).”
BackgroundAMPK in Cardiovascular Diseases
Daskalopoulos, E. P., Dufeys, C., Beauloye, C., Bertrand, L., & Horman, S. (2016) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-319-43589-3_8 · Cited by 52
Shoukry, H. S., Ammar, H. I., Rashed, L. A., Zickri, M. B., Shamaa, A., Elfadl, S. A., Abu‐El‐Rub, E., Sekaran, S., & Dhingra, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181535 · Cited by 53
AMP-Activated Protein Kinase: Potential Role in Cardiac Electrophysiology and Arrhythmias
Harada, M., Nattel, S. N., & Nattel, S. (2012) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.112.972265 · Cited by 52
“aortic constriction–induced cardiac hypertrophy through inhibition of protein synthetic signaling.(18,19) AMPK activa-”
BackgroundMitochondrial sirtuins in the heart
Bugger, H., Witt, C. N., & Bode, C. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9570-7 · Cited by 48
Basavarajappa, S. C., & Nandini, C. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.12.031 · Cited by 49
Haye, A., Ansari, M. A., Rahman, S. O., Shamsi, Y., Ahmed, D., & Sharma, M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173376 · Cited by 50
Protective effects of plant‐derived natural products on renal complications
Yaribeygi, H., Simental‐Mendía, L. E., Butler, A. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27950 · Cited by 46
“(Chan et al., 2008; Chi et al., 2007; Hung, & Chen, 2004; Kumar & Sharma, 2013; Singh CK & Ahmad, 2015; Su, Hung, & Chen, 2006; Xu et al., 2014), though its putative cardioprotective actions have”
BackgroundProtective effects of berry polyphenols against age-related cognitive impairment
Bensalem, J., Dal‐Pan, A., Gillard, E., Calon, F., & Pallet, V. (2015) · Nutrition and Aging · doi:10.3233/nua-150051 · Cited by 48
“[145] Chan AY, Dolinsky VW, Soltys CL, Viollet B, Baksh S, Light PE, et al.”
BackgroundRole of resveratrol in inhibiting pathological cardiac remodeling
Fan, S., Hu, Y., You, Y., Xue, W., Chai, R., Zhang, X., Shou, X., & Shi, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.924473 · Cited by 48
“Among them, P70S6K regulates protein translation and extension (Chan et al., 2008).”
BackgroundResveratrol prevents pathological but not physiological cardiac hypertrophy
Dolinsky, V. W., Soltys, C.-L. M., Rogan, K. J., Chan, A. Y. M., Nagendran, J., Wang, S., & Dyck, J. R. B. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1220-8 · Cited by 48
“In contrast to our previous report using higher concentrations of Resv [6], Resv treatment (0.”
Self-citationTargeting AMPK: From Ancient Drugs to New Small-Molecule Activators
Guigas, B., & Viollet, B. (2016) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-319-43589-3_13 · Cited by 46
Self-citationDarby, J. R. T., Saini, B. S., Soo, J. Y., Lock, M. C., Holman, S. L., Bradshaw, E. L., McInnes, S. J. P., Voelcker, N. H., Macgowan, C. K., Seed, M., et al. (2019) · The Journal of Physiology · doi:10.1113/jp278110 · Cited by 45
“There is evidence for direct action of RSV-mediated SIRT1 activation on the heart, whereby increased SIRT1 activity is protective against both phenylephrine (Chan et al. 2008) and pressure-induced cardiac hypertrophy in rats (Juric et al.”
BackgroundLuther, D. J., Ohanyan, V. A., Shamhart, P. E., Hodnichak, C. M., Sisakian, H. S., Booth, T. D., Meszaros, J. G., & Bishayee, A. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9332-7 · Cited by 44
Vetterli, L., & Maechler, P. (2011) · Aging · doi:10.18632/aging.100304 · Cited by 51
“Resveratrol stimulates AMPK in HepG2 hepatoma [18] and INS-1E insulinoma [14] cell lines, as well as in various tissues [19-21].”
BackgroundLouis, X. L., Thandapilly, S. J., Mohankumar, S. K., Yu, L., Taylor, C. G., Zahradka, P. C., & Netticadan, T. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.06.010 · Cited by 49
Baczkó, I., Liknes, D. A., Yang, W., Hamming, K. S. C., Searle, G. J., Jaeger, K., Husti, Z., Juhász, V., Klausz, G., Pap, R., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12409 · Cited by 44
“24h prior to the initiation of experiments, the medium was changed to serum-free DMEM/F-12 containing 50 μg ml gentamicin supplemented with 1× insulin, transferrin, sodium selenite (ITS)+3 liquid media supplement (Chan et al., 2008).”
BackgroundMethodInfluentialSelf-citationAnestopoulos, I., Kavo, A. E., Tentes, I. K., Kortsaris, A., Panayiotidis, M. I., Lazou, A., & Pappa, A. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.02.009 · Cited by 50
“In the last few years, several natural plant antioxidant compounds like resveratrol (a polyphenolic compound present in grapes) [47–49] and green tea extracts (catechins, epigallocatechin gallate, etc.”
BackgroundFan, Y., Liu, L., Fang, K., Huang, T., Wan, L., Liu, Y., Zhang, S., Yan, D., Li, G., Gao, Y., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002648 · Cited by 43
“disclosed that Rev exerted antihypertrophic effects by activating AMPK by LKB1 and inhibiting Akt, thus suppressing protein synthesis and gene transcription in pathological cardiac hypertrophy.(25) The present study”
BackgroundAMPK signalling and the control of substrate use in the heart
Nagendran, J., Waller, T. J., & Dyck, J. R. B. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.015 · Cited by 47
Self-citationThe effects of resveratrol and SIRT1 activation on dystrophic cardiomyopathy
Kuno, A., Tanno, M., & Horio, Y. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12812 · Cited by 43
Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology
Abdelgawad, I. Y., Grant, M. K. O., & Zordoky, B. N. M. (2019) · Nutrients · doi:10.3390/nu11030627 · Cited by 42
“Resveratrol has been shown to activate AMP-activated protein kinase (AMPK) [35], sirtuin 1 (SIRT1) [36,37], super oxide dismutase (SOD) [38], nuclear factor erythroid 2–related factor 2 (NRF2) [39], vascular endothelial growth factor (VEGF) [40], and endothelial nitric oxide synthase (eNOS) [37,41].”
BackgroundInfluentialTargeting histone deacetylases for heart failure
Bush, E. W., & McKinsey, T. A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902939161 · Cited by 43
“However, it should be noted that many HDAC-independent functions of resveratrol have been described [191], and the antihypertrophic action of the compound was recently attributed to activation of AMP-activated protein kinase (AMPK) [187].”
Oleic Acid Protects from Arsenic-Induced Cardiac Hypertrophy via AMPK/FoxO/NFATc3 Pathway
Samanta, J., Mondal, A., Saha, S., Chakraborty, S., & Sengupta, A. (2019) · Cardiovascular Toxicology · doi:10.1007/s12012-019-09550-9 · Cited by 41
The Biology and Therapeutic Implications of HDACs in the Heart
McKinsey, T. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-21631-2_4 · Cited by 41
“However, it should be noted that many HDAC-independent functions of resveratrol have been described (Pirola and Frojdo 2008), and the antihypertrophic action of the compound was recently attributed to activation of AMP-activated Protein Kinase (AMPK) (Chan et al. 2008).”
BackgroundBarangi, S., Hayes, A. W., & Karimi, G. (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1379000 · Cited by 43
“vated kinase (AMPK) which seems implicated in the development of AF (Chan et al. 2008).”
BackgroundWu, L., Li, F., Zhao, C.-Y., Yao, M., Zheng, C., Li, Y., Lei, S.-H., & Chen, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104488 · Cited by 40
Protective effects of ginsenoside Rc against acute cold exposure‐induced myocardial injury in rats
Xue, Y., Yu, X., Zhang, X., Yu, P., Li, Y., Fu, W., Yu, J., & Sui, D. (2021) · Journal of Food Science · doi:10.1111/1750-3841.15757 · Cited by 39
Natural AMPK Activators in Cardiovascular Disease Prevention
Moghaddam, R. H., Samimi, Z., Asgary, S., Mohammadi, P., Hozeifi, S., Hoseinzadeh‐Chahkandak, F., Xu, S., & Farzaei, M. H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.738420 · Cited by 45
“Researchers have noted that acute treatment with resveratrol (100 μmol/L) can reduce cell growth in rat cardiac myocytes by increasing AMPK and ACC phosphorylation as well as inhibiting Akt activation in the hypertrophic process (Chan et al., 2008).”
BackgroundIs alcohol beneficial or harmful for cardioprotection?
Lakshman, M., Garige, M., Gong, M., Leckey, L. C., Varatharajalu, R., & Zakhari, S. (2009) · Genes & Nutrition · doi:10.1007/s12263-009-0161-2 · Cited by 39
“Each value is the mean ± SD of six independent determinations eNOS, iNOS, COX-1, COX-2, Trx-1 and Trx-2 [119].”
BackgroundInfluentialWang, L., Halliday, G., Huot, J. R., Satoh, T., Baust, J., Fisher, A. J., Cook, T. G., HU, J. L., Avolio, T., Goncharov, D. A., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313883 · Cited by 39
Dolinsky, V. W., & Dyck, J. R. B. (2014) · Molecules · doi:10.3390/molecules190914919 · Cited by 42
“While numerous pathways could be responsible for these anti-hypertrophic effects, it was demonstrated that resveratrol could not inhibit most of the NFAT-dependent transcription in MEFs lacking AMPK, providing evidence that suppression of the calcineurin-NFAT pathways requires AMPK activation [148].”
BackgroundInfluentialSelf-citationZordoky, B. N. M., & El‐Kadi, A. O. S. (2009) · Toxicology in Vitro · doi:10.1016/j.tiv.2009.12.002 · Cited by 36
Chen, M., Cai, H., Chang, Y., Wu, P., Fu, Y., Xu, X., Fan, R., Xu, C., Chen, Y., Wang, L., et al. (2016) · Europe PMC (PubMed Central) · Cited by 36
Perspectives of Targeting mTORC1–S6K1 in Cardiovascular Aging
Ming, X., Montani, J., & Yang, Z. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00005 · Cited by 38
“In addition, drugs more specifically inhibiting S6K1 rather than mTORC1 should be developed and the effects of targeting mTORC1 or S6K1 on aging-related cardiovascular diseases and cardiovascular aging and beyond should be investigated.”
BackgroundFolmes, K. D., Chan, A. Y. M., Koonen, D. P. Y., Pulinilkunnil, T., Baczkó, I., Hunter, B., Thorn, S., Allard, M. F., Roberts, R., Gollob, M. H., et al. (2009) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.108.834564 · Cited by 37
Self-citationResveratrol induces nuclear factor-κB activity in human cardiac cells
Palomer, X., Capdevila-Busquets, E., Álvarez-Guardia, D., Barroso, E., Pallàs, M., Camins, A., Davidson, M. M., Planavila, A., Villarroya, F., & Vázquez‐Carrera, M. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.06.006 · Cited by 38
“Resveratrol prevents cardiac hypertrophy, metabolic dysregulation, and inflammatory response in several murine models in vitro and in vivo [17,18], but little is known about its effects on human cardiac cells.”
BackgroundPung, Y. F., Sam, W. J., Stevanov, K., Enrick, M., Chen, C., Kolz, C. L., Thakker, P., Hardwick, J. P., Chen, Y., Dyck, J. R. B., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301591 · Cited by 35
Self-citationPan, Z., Zhang, Y., Mei, D.-H., Zhang, R., Wang, J., Zhang, X., Xu, C., Lu, Y., & Yang, B. (2010) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-009-0484-y · Cited by 33
“2006), and resveratrol (Chan et al. 2008), were demonstrated to exert apparent anti-hypertrophic action on the heart via diverse signaling pathways.”
BackgroundAkhondzadeh, F., Astani, A., Najjari, R., Samadi, M., Rezvani, M. E., Zare, F., Ranjbar, A. M., & Safari, F. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29592 · Cited by 34
Ligand Activation of Cannabinoid Receptors Attenuates Hypertrophy of Neonatal Rat Cardiomyocytes
Lu, Y., Akinwumi, B. C., Shao, Z., & Anderson, H. D. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000134 · Cited by 35
Ding, W., Dong, M., Deng, J., Yan, D., Liu, Y., Xu, T., & Liu, J. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00017.2014 · Cited by 32
Rohrbach, S., Aslam, M., Niemann, B., & Schulz, R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12650 · Cited by 38
“Resveratrol also prevents cardiac hypertrophy in SHR both by reducing haemodynamic load (Dolinsky and Dyck, 2011) and by direct action on cardiomyocytes (Chan et al., 2008) and has been proven beneficial by reducing myocardial infarct size and improving post-ischaemic functional recovery (Ray et al.”
BackgroundResveratrol and derivatives for the treatment of atrial fibrillation
Baczkó, I., & Light, P. E. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12843 · Cited by 32
Self-citationLKB1: An emerging therapeutic target for cardiovascular diseases
Molaei, A., Molaei, E., Sadeghnia, H. R., Hayes, A. W., & Karimi, G. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120844 · Cited by 33
UCF-101 mitigates streptozotocin-induced cardiomyocyte dysfunction: role of AMPK
Li, Q., Li, J., & Ren, J. T. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00323.2009 · Cited by 29
RetractedLu, Y., Lu, X., Wang, L., & Yang, W. P. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.018 · Cited by 28
“In obese mouse studies, resveratrol administration decreases cardiac hypertrophy and improves diastolic dysfunction (Chan et al., 2008).”
AMP-Activated Protein Kinase Signalling in Cancer and Cardiac Hypertrophy
Konhilas, Y. L. J. P. (2015) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000154 · Cited by 30
“This is mainly achieved by targeting the mTOR pathway [81,82].”
BackgroundGan, W., Dang, Y., Han, X., Ling, S., Duan, J., Liu, J., & Xu, J. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500466 · Cited by 30
Role of AMP-Activated Protein Kinase in Ferritin H Gene Expression by Resveratrol in Human T Cells
Iwasaki, K., Ray, P. D., Huang, B., Sakamoto, K., Kobayashi, T., & Tsuji, Y. (2013) · Biochemistry · doi:10.1021/bi400399f · Cited by 28
Chakraborty, P., Nattel, S., & Nanthakumar, K. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.03.025 · Cited by 27
Resveratrol inhibits mTOR signaling by targeting DEPTOR
Liu, M., & Liu, F. (2011) · Communicative & Integrative Biology · doi:10.4161/cib.15309 · Cited by 32
CSRP3 mediates polyphenols-induced cardioprotection in hypertension
Oudot, C., Gomes, A., Nicolas, V., Gall, M. L., Chaffey, P., Broussard, C., Calamita, G., Mastrodonato, M., Gena, P., Perfettini, J., et al. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.01.001 · Cited by 27
Zhu, Y., Takayama, T., Wang, B., Kent, A. M., Zhang, M., Binder, B. Y. K., Urabe, G., Shi, Y., DiRenzo, D. M., Goel, S. A., et al. (2017) · Scientific Reports · doi:10.1038/srep41916 · Cited by 29
Hu, Y. X., Cui, H., Fan, L., Pan, X. J., Wu, J., Shi, S. Z., Cui, S. Y., Wei, Z. M., & Liu, L. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2012-0464 · Cited by 25
Resveratrol against Cardiac Fibrosis: Research Progress in Experimental Animal Models
Yu, D., Tang, Z., Li, B., Yu, J., Li, W., Liu, Z., & Tian, C. (2021) · Molecules · doi:10.3390/molecules26226860 · Cited by 27
“of hypertrophic Akt signal pathway [34].”
BackgroundDifferential regulation of eEF2 and p70S6K by AMPKalpha2 in heart
Demeulder, B., Zarrinpashneh, E., Ginion, A., Viollet, B., Hue, L., Rider, M. H., Vanoverschelde, J., Beauloye, C., Horman, S., & Bertrand, L. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.02.015 · Cited by 23
“Concerning the heart, we [31] and others [25,27] have previously shown that pharmacological activation of AMPK was found to inhibit both p70S6K and eEF2.”
BackgroundSelf-citationEmerging roles of Sirtuin 2 in cardiovascular diseases
Taneja, A., Ravi, V., Hong, J. Y., Lin, H., & Sundaresan, N. R. (2021) · The FASEB Journal · doi:10.1096/fj.202100490r · Cited by 24
Mashhadi, F. D., Reza, J. Z., Jamhiri, M., Hafizi, Z., Mehrjardi, F. Z., & Safari, F. (2016) · The Journal of Physiological Sciences · doi:10.1007/s12576-016-0465-0 · Cited by 22
“In cultured cardiomyocytes, treatment with resveratrol limits the induced hypertrophic response with phenylephrine [8].”
Modulation of mitochondrial dysfunction for treatment of disease
Webb, M., Sideris, D. P., & Biddle, M. M. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.041 · Cited by 25
Samie, S. M. A., & Nasr, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821222-6.00011-7 · Cited by 21
Raut, G. K., Manchineela, S., Chakrabarti, M., Bhukya, C. K., Naini, R., Venkateshwari, A., Reddy, V. D., Mendonza, J. J., Suresh, Y., Nallari, P., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.04.014 · Cited by 22
Activated protein C protects against pressure overload-induced hypertrophy through AMPK signaling
Cates, C. A., Rousselle, T. V., Wang, J., Quan, N., Wang, L., Chen, X., Yang, L., Rezaie, A. R., & Li, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.125 · Cited by 21
“This is in agreement with reports that AMPK activity increased in the rat heart with pressure overload-induced hypertrophy [4,7,33].”
BackgroundChloroquine increases phosphorylation of AMPK and Akt in myotubes
Spears, L. D., Tran, A. V., Qin, C. Y., Hobbs, S. B., Burns, C. A. L., Royer, N. K., Zhang, Z., Ralston, L., & Fisher, J. S. (2016) · Heliyon · doi:10.1016/j.heliyon.2016.e00083 · Cited by 20
“This phenomenon has been reported previously, though not in myotubes to our knowledge [26, 27].”
BackgroundCai, Y., Zhao, L., Qin, Y. H., & Wu, X. (2015) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2015.19.3.203 · Cited by 19
“Moreover, Activation of AMPK also result in decreased p70S6 kinase phosphorylation and increased phosphorylation of eEF2, suggesting that inhibition of protein synthesis involves the eEF2 kinase/eEF2 axis and/or the p70S6 kinase pathway [29].”
BackgroundThe Phytostilbene Resveratrol Induces Apoptosis in INS-1E Rat Insulinoma Cells
Bortolotti, C., Kunit, T., Moder, A., Hufnagl, C., Schmidt, S., Hartl, A. J., Langelueddecke, C., rst, J. F. U., Geibel, J. P., Ritter, M., et al. (2009) · Cellular Physiology and Biochemistry · doi:10.1159/000218171 · Cited by 19
Dubois‐Deruy, E., Gélinas, R., Beauloye, C., Esfahani, H., Michel, L. Y. M., Dessy, C., Bertrand, L., & Balligand, J. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12648 · Cited by 17
Engineering Injectable Anti‐Inflammatory Hydrogels to Treat Acute Myocardial Infarction
Zhang, X., & Liu, W. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200008 · Cited by 16
Akinwumi, B. C., Raj, P., Lee, D. I., Acosta, C., Yu, L., Thomas, S. M., Nagabhushanam, K., Majeed, M. A., Davies, N. M., Netticadan, T., et al. (2017) · Molecules · doi:10.3390/molecules22020204 · Cited by 18
“This is consistent with previous reports first, of the ability of resveratrol to prevent cardiomyocyte hypertrophy in vitro, in response to stimuli such as angiotensin II [28,29], phenylephrine [30], and norepinephrine [31], and second, of the anti-hypertrophic role of AMPK [29,31].”
BackgroundResultLee, D. I., Acosta, C., Anderson, C. M., & Anderson, H. D. (2017) · Molecules · doi:10.3390/molecules22030380 · Cited by 21
“Finally, resveratrol effects on the hypertrophied heart are reportedly attributable to effects on AMPK signaling [50].”
Moon, D. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08746-1 · Cited by 17
A novel complex I inhibitor protects against hypertension-induced left ventricular hypertrophy
Matsumura, N., Robertson, I. M., Hamza, S. M., Soltys, C.-L. M., Sung, M. M. Y., Masson, G., Beker, D. L., & Dyck, J. R. B. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00604.2016 · Cited by 15
“Since we and others have previously shown that AMPK activation also results in the inhibition of known molecular markers controlling protein synthesis that are associated with regulating hypertrophic growth (3, 5, 41), we also examined the phosphorylation status of eEF2 at threonine 56 and mTOR at serine 2448.”
BackgroundMethodInfluentialSelf-citationde Oliveira, J. C., Antonietto, C. R. K., Scalabrini, A. C., Marinho, T. S., Pernomian, L., Corrêa, J. W. D. N., & Restini, C. B. A. (2012) · Open Journal of Medicinal Chemistry · doi:10.4236/ojmc.2012.23008 · Cited by 13
“Previous reports indicate that these effects may include the activation of the anti-hypertrophic AMPK-signaling pathway and inhibition of the prohypertrophic Akt signaling pathway and negative regulation of the calcineurin-nuclear factor of activated T cells (NFAT) pathway [64].”
Wang, J., Liu, Z., Feng, X., Gao, S., Xu, S., & Liu, P. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.08.007 · Cited by 12
Rostami, A., Palomer, X., Pizarro‐Delgado, J., Peña, L., Zamora, M., Montori-Grau, M., Barroso, E., Valenzuela‐Alcaráz, B., Crispi, F., Salvador, J. M., et al. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05704-x · Cited by 11
5′-AMP-activated protein kinase is inactivated by adrenergic signalling in adult cardiac myocytes
Tsuchiya, Y., Denison, F. C., Heath, R. B., Carling, D., & Saggerson, D. (2011) · Bioscience Reports · doi:10.1042/bsr20110076 · Cited by 12
Studying the Role of AMPK in Cardiac Hypertrophy and Protein Synthesis
Mailleux, F., Beauloye, C., Balligand, J., Horman, S., & Bertrand, L. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7598-3_21 · Cited by 11
Casimir, M., Chaffard, G., & Maechler, P. (2018) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-018-2215-z · Cited by 11
Flores, K., Siqués, P., Brito, J., Ordenes, S., Arriaza, K., Pena, E., Lèon‐Velarde, F., López, R., de Pablo, Á. L. L., & Arribas, S. M. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00342 · Cited by 12
Shah, M., Dave, B. P., Bhagat, S. U., Rao, H. J., Khadela, A. D., & Nisha, P. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00609-1 · Cited by 13
“In addition to this, it has also been shown to regulate various pathways associated with cellular maturation and death such as MAPK, protein kinase B (Akt), protein kinase C, and peroxisome proliferator activated receptor-gamma (PPAR-ϒ ) [70–72].”
BackgroundRole of AMPK in Diabetic Cardiovascular Complications: An Overview
Nellaiappan, K., Yerra, V. G., & Kumar, A. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180508104929 · Cited by 9
A Computational Method for Unveiling the Target Promiscuity of Pharmacologically Active Compounds
Schneider, P., & Schneider, G. (2017) · Angewandte Chemie · doi:10.1002/ange.201706376 · Cited by 8
Ando, S., Kojima, N., Moyama, C., Fujita, M., Ohta, K., Ii, H., & Nakata, S. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12754 · Cited by 9
AMPK and O-GlcNAcylation: interplay in cardiac pathologies and heart failure
Vanni, E., Beauloye, C., Horman, S., & Bertrand, L. (2024) · Essays in Biochemistry · doi:10.1042/ebc20240003 · Cited by 8
Li, M., Tang, Y., Du, R., Shi, F., Hussein, H. K., Dai, D., & Dai, Y. (2015) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12401 · Cited by 8
“On the other hand, adenine mono-phosphate kinase (AMPK) may decrease oxidative stress via modulating NOX in the cardiovascular system([17]) and an activation of AMPK mitigates ischaemic injury and hypertrophy.”
BackgroundKamvar, R., Barjasteh, A. H., Omouri‐Kharashtomi, M., Roumiani, P. H., Beheshtirooy, A., Adib-Hajbagheri, P., Rezaei, P., Shokraei, R., & Pourhanifeh, M. H. (2025) · European journal of medical research · doi:10.1186/s40001-025-03235-6 · Cited by 7
“This pathway typically helps prevent cardiac hypertrophy by inhibiting anabolic processes like protein synthesis [70].”
Chen, B., Wu, Q., Xiong, Z., Ma, Y., Yu, S., Chen, D., Huang, S., & Dong, Y. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw076 · Cited by 7
Elkhatib, M. A. W., Gerges, S. H., Isse, F. A., & El‐Kadi, A. O. S. (2024) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2024-0037 · Cited by 6
Yasmin, T., Alimullah, M., Rahman, M. J., Sultana, S., Siddiqua, S., Jahan, I., Rana, S., Subhan, N., Khan, F., Alam, M. A., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118571 · Cited by 6
Baczkó, I., Leprán, I., Kiss, L., Muntean, D. M., & Light, P. E. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666141029101305 · Cited by 7
“Resveratrol has been shown to inhibit NFAT activation [314], a pathway implicated in AF [315] and pathological cardiac hypertrophy [316].”
BackgroundSelf-citation
Metadata
- Authors
- Chan, A. Y. M., Dolinsky, V. W., Soltys, C.-L. M., Viollet, B., Baksh, S., Light, P. E., & Dyck, J. R. B.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Dyck, Jason R.B.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 283
- Issue
- 35
- Pages
- 24194-24201
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC3259789
- OpenAlex
- W2091412980
- Cited by
- 244
- References
- 40
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 12 · 2019: 10 · 2018: 16 · 2017: 15 · 2016: 14 · 2015: 19 · 2014: 15 · 2013: 18 · 2012: 21
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4445 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Heart and Stroke Foundation of Canada
- European Commission (LSHMCT-2004-005272)
- Agence Nationale de la Recherche
- Fondation pour la Recherche Médicale
- Alberta Heritage Foundation for Medical Research
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- resveratrol, cardiac hypertrophy, AMPK, Akt, LKB1, cardiomyocytes, p70 S6 kinase, elongation factor 2, calcineurin/NFAT signaling, protein synthesis, phenylephrine, gene transcription
- MeSH terms
- Resveratrol, AMP-Activated Protein Kinase Kinases, Animals, Cardiotonic Agents, Cells, Cultured, Enzyme Activation, Enzyme Inhibitors, Cardiomegaly, Multienzyme Complexes, Phenylephrine, Stilbenes, Transcription, Genetic, Protein Biosynthesis, Protein Serine-Threonine Kinases, Peptide Elongation Factor 2, Myocytes, Cardiac, Ribosomal Protein S6 Kinases, 70-kDa, Proto-Oncogene Proteins c-akt, Mice, Rats, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.